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Abstract
Exploratory studies using human fetal tissue have suggested that intrastriatal transplanta-
tion of dopaminergic neurons may become a future treatment for patients with Parkinson’s
disease. However, the use of human fetal tissue is compromised by ethical, regulatory and
practical concerns. Human stem cells constitute an alternative source of cells for transplan-
tation in Parkinson’s disease, but efficient protocols for controlled dopaminergic differentia-
tion need to be developed. Short-term, low-level carbon monoxide (CO) exposure has been
shown to affect signaling in several tissues, resulting in both protection and generation of
reactive oxygen species. The present study investigated the effect of CO produced by a
novel CO-releasing molecule on dopaminergic differentiation of human neural stem cells.
Short-term exposure to 25 ppm CO at days 0 and 4 significantly increased the relative con-
tent of β-tubulin III-immunoreactive immature neurons and tyrosine hydroxylase expressing
catecholaminergic neurons, as assessed 6 days after differentiation. Also the number of
microtubule associated protein 2-positive mature neurons had increased significantly. More-
over, the content of apoptotic cells (Caspase3) was reduced, whereas the expression of a
cell proliferation marker (Ki67) was left unchanged. Increased expression of hypoxia induc-
ible factor-1α and production of reactive oxygen species (ROS) in cultures exposed to CO
may suggest a mechanism involving mitochondrial alterations and generation of ROS. In
conclusion, the present procedure using controlled, short-term CO exposure allows efficient
dopaminergic differentiation of human neural stem cells at low cost and may as such be
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Introduction
Parkinson’s disease is a neurodegenerative disorder affecting more than six million people
worldwide [1]. The disease is associated with a progressive loss of midbrain dopaminergic neu-
rons and subsequent depletion of striatal dopamine. Cardinal symptoms include bradykinesia,
rigidity, tremor and postural instability, but non-motor symptoms also occur [2].
Several explorative clinical studies using human fetal ventral mesencephalic tissue have
indicated that intrastriatal transplantation may become a future treatment for Parkinson’s dis-
ease [3–8]. However, the use of human fetal tissue is hampered by ethical concerns, suboptimal
survival of grafted dopaminergic neurons, development of postgrafting dyskinesias in some
patients, and the logistics related to collection and storage of the donor tissue [5,8–13].
Pre-differentiated induced pluripotent stem cells, embryonic stem cells and NSCs represent
potential alternative sources of cells for cell replacement therapy in Parkinson’s disease. NSCs
are self-renewable multipotent cells that can be isolated from the developing and mature ner-
vous system. Such cells may have significant advantages compared to human fetal tissue as
they can be propagated to almost unlimited numbers of relatively homogenous cells in vitro
and frozen without significant loss of viability [14,15]. Nevertheless, efficient, simple and cost-
effective protocols for controlled generation of functional dopaminergic neurons are still not
available.
CO is an endogenous product of heme degradation, a reaction catalyzed by the enzyme
heme oxygenase [16]. This gasotransmitter shows several beneficial biological activities and
has been the target of extensive studies in relation to cardiovascular diseases, inflammatory
disorders and organ transplantation [17]. The great potential of CO in biomedical applications
has prompted development of several delivery strategies of CO for therapeutic or research
purposes. Gas inhalation is the most simple strategy and has been greatly used in pre-clinical
in vivo experiments [18–20]. Cell cultures can also be exposed to CO in gas chambers as
described for neurons [21] and macrophages [22]. Another possible strategy for in vitro
application of CO is the use of CO-saturated solutions [23,24]. Nevertheless, for all these
approaches CO gas bottles are handled with the potential risk of leaking the odorless and
highly toxic gas. Furthermore, gas inhalation is not the most appropriate method for CO
administration in a clinical context, since it promotes increased carboxyhaemoglobin levels as
well as CO delivery to both healthy and diseased tissues. Therefore, CO-releasing molecules
(CORMs) providing controlled CO delivery have been developed [25]. The most studied non-
metal based CORM is boranocarbonate [H3BCO2]Na2 (CORM-A1), which in several studies
has been shown to modulate cytoprotection, hormesis and inflammation [26–28]. There are
also many metal-based compounds studied in biological systems, and the most explored is the
water-insoluble dimer [Ru(CO)3Cl2]2 (CORM-2) and its water soluble derivative Ru(CO)3Cl
(κ2-H2NCH2CO2) (CORM-3). CORM-2 and CORM-3 have been tested in pre-clinical studies
of cardioprotection [29,30], inflammation [31–33], neuroprotection [34–36], transplantation
[37] and pain [38].
In the CNS, the CO/heme oxygeanse axis is a key player in processes involved in cytopro-
tection, vasomodulation, neuroinflammation, cell death, metabolism and cellular redox
responses [39]. CO was first recognized as a neurotransmitter by Verma and colleagues [40],
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and their work led to extensive research on CO and heme oxygenase in the nervous system.
Interestingly, both heme oxygenase and exogenous administration of CO were reported to
stimulate neuroprotection and maintenance of tissue homeostasis in response to various
pathophysiological conditions; including cerebral ischemia [20,36,41–43], cerebrovasodilation
[28,44,45], neuroinflammatory [19,34,35,46], and neurodegenerative diseases [47–49].
The CO-induced pathways and putative targets are a matter of debate. Nevertheless, it is
well accepted that CO activates soluble guanylyl cyclase and nitric oxide synthase, increasing
the cGMP and nitric oxide levels, respectively, whose best described effects are modulation
of vasodilation [50]. In neurons, CO-induced cGMP production is involved in protection
against cell death [21,36,51]. Nitric oxide signaling is related to anti-inflammatory effect of CO
in microglia [32].
In CO pathways, low amounts of reactive oxygen species play a crucial role in precondition-
ing and cytoprotection in neurons and astrocytes [21,24]. Interestingly, Chin and colleagues
have demonstrated CO-mediated stabilization of HIF-1α [52], although it is a controversial
subject [53].
In the present study two major novelties are approached. Firstly, the potential effect of CO
on dopaminergic differentiation of human NSCs is assessed. Secondly, a new strategy for deliv-
ering CO gas is being tested. In this new system, CO is generated by a decarbonylation reaction
using the new CORM methyldiphenylsilacarboxylic acid (MePh2SiCO2H), along with the
non-transition-metal activator potassium fluoride and dimethyl sulfoxide [54]. This strategy
avoids the use of CO gas bottles, thus being safer and more cost-effective than previously
described methods.
Materials and methods
Carbon monoxide releasing molecules (CORMs)
CORMs are chemical compounds typically containing transition-metal carbonyl complexes
that can release CO under certain conditions [55]. We used a crystalline silacarboxylic acid,
which was synthesized from the corresponding chlorosilane via reduction with metallic lith-
ium, and allowed it to react with CO2 [54]. By mixing methyldiphenylsilacarboxylic acid
(MePh2SiCO2H) with the non-transition-metal activator potassium fluoride (Sigma) and the
solvent dimethyl sulfoxide (Sigma) a decarbonylation reaction results in CO-release (Fig 1a)
[54]. For the present study, a plexi-glass chamber was developed (Fig 1b). In order to achieve
controlled CO concentrations we used 1 mg MePh2SiCO2H, 0.3 mg potassium fluoride and
62.5 μl dimethyl sulfoxide per mg MePh2SiCO2H to generate 7.4 ppm CO in the chamber. The
amount of solids required to achieve a predefined level of CO (12,5–100 ppm) were placed in a
glass vial (Supelco) and transferred to the exposure chamber together with the culture plates/
flasks (none of the solids entered the culture medium). The CO concentration in the chamber
was monitored with a Dra¨ger Pac 7000 CO sensor device (Dra¨ger Safety AG & Co. KGaA,
Lu¨beck, Germany). The chamber was placed at 36˚C, 5% CO2 and 95% humidified air. To
start CO release, dimethyl sulfoxide was lead through a separator in the wall of the chamber
and into the vial with silacarboxylic acid/potassium flouride. A ventilator homogenized the
concentration of gas in the closed atmosphere (Fig 1b). The CO concentration was measured
throughout all experiments (S1 Fig).
Culturing and passaging of NSCs
Tissue procurement was in accordance with the Declaration of Helsinki and in agreement
with national and institutional rules as well as the ethical guidelines of Network of European
CNS Transplantation and Restoration (NECTAR).
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Two human ventral mesencephalic (VM) stem cell lines generated in previous studies
were used (hVMbclXL; hReN). In brief, VM cells were derived from a 10-week-old foetus and
immortalized using a retroviral vector coding for v-myc (LTR-vmyc-SV40p-Neo-LTR), creat-
ing a multipotent cell line (hVM1) [56]. The hVM1 cells were genetically modified (MLV-
based retroviral vector) to over-express the anti-apoptotic gene BclXL (LTR-Bcl-XL-IRES-
rhGFP-LTR), essentially as described by Liste et al. [57].
Fig 1. Chemical reaction releasing carbon monoxide (CO) and experimental setup. (a) The chemical reaction
releasing CO when mixing methyldiphenylsilacarboxylic acid (MePh2SiCO2H), potassium fluoride and dimethyl
sulfoxide. (b) Illustration of the CO gas chamber. (c) Human neural stem cells were plated at day 0, cultured for 4 hrs
followed by one or two 30 min CO treatments. All culture medium was changed at days 4, 6 and 9. hREN VM cell
cultures received CO treatment at days 0 and 4 and were used for immunocytochemistry and Western blotting after 6
days. For experiments with hVMbclXL cells: 1) cultures received CO treatment at day 0 followed by
immunocytochemistry at days 1, 6 and 10, or 2) cultures received CO treatment at days 0 and 4 and were used for
cytokine profiling (day 5), immunocytochemistry (day 6 and 10), Western blotting (day 6) or MTS assay (day 6).
Untreated control cultures were included in all experiments. DIV = days in vitro.
https://doi.org/10.1371/journal.pone.0191207.g001
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Cells were propagated in poly L-lysine (10 μg/ml; Sigma)-coated culture flasks containing
HNSC100 medium (Dulbecco’s modified Eagle’s medium F12 w. Glutamax (Gibco), 2% (v/v)
30% glucose (Sigma), 0.5% (v/v) 1 M Hepes (Gibco), 2.5% (v/v) AlbuMAX-I (Gibco), 1% (v/v)
N2 supplement (Gibco), 1% (v/v) NEAA (Sigma) and 1% penicillin/streptomycin (Gibco))
supplemented with 20 ng/ml epidermal growth factor (R&D Systems) and 20 ng/ml basic
fibroblast growth factor (R&D Systems) at 36˚C, 5% CO2/95% humidified air. Medium was
changed every third day, and cells passaged at 80% confluence. Cells were counted using an
automatic cell counter (S2 Fig).
The hREN VM cell line was derived from a 10-week-old foetus (ReNeuron; Millipore) and
immortalized by retroviral transfection with the oncogene v-myc [58]. hREN VM cells were
cultured as described above.
Neuronal differentiation protocols
NSCs were passaged and plated into poly L-lysine-coated 24-/96-well trays or T75 culture
flasks (Nunc, Sigma) with HNSC100 medium (26,000 cells/cm2). Both cell lines, hVMbclXL
(passage 26–29) and hREN VM (passage 7), were exposed to CO for 30 min (hVMbclXL cells
also for 45 and 60 min). Untreated cultures served as controls.
hVMbclXL cultures either received CO treatment at day 0 followed by differentiation for
1, 6 and 10 days or were exposed to CO at days 0 and 4 and differentiated until day 6 or 10
(Fig 1c).
hREN VM cells received CO treatment at days 0 and 4 and were differentiated until day 6.
The culture medium was changed every third day.
Neurospheres
Cells (hVMbclXL) were plated (233,000 cells/ml medium) in 35 mm petri dishes (Nunc;
Sigma) with 4.3 ml HNSC100 medium containing 20 ng/ml epidermal growth factor and basic
fibroblast growth factor (R&D Systems) and grown at 36˚C in 5% CO2/and 95% humidified
air. Resulting neurospheres received 25 ppm CO for 30 min at days 0 and 4 versus untreated
controls. At day 9, all neurospheres were processed for immunohistochemistry.
Fixation and immunocytochemistry
Monolayer cultures were fixed (20 min) in 4% paraformaldehyde/0.15M phosphate buffer. For
immunocytochemistry cultures were washed in 0.05M tris-buffered saline (TBS) containing
0.1% triton X-100 (Sigma) and pre-incubated (30 min) in TBS/10% donkey or sheep serum
(Gibco). Primary antibodies (24 hrs; 4˚C) were diluted in TBS/10% donkey or sheep serum:
Tyrosine hydroxylase (TH; polyclonal rabbit; Chemicon) 1:600; β-tubulin III (β-tubIII; mono-
clonal mouse; Sigma) 1:2000; human nuclei (HN; monoclonal mouse; Chemicon) 1:500;
microtubule associated protein 2ab (MAP2; monoclonal mouse; Sigma) 1:2000; Ki67 (mono-
clonal mouse; BD Pharmigen) 1:500; active/cleaved caspase3 (Casp3; polyclonal rabbit; R&D
Systems) 1:5000.
Cultures were then incubated for 1 hr with biotinylated anti-rabbit or anti-mouse antibod-
ies (GE Healtcare) diluted 1:200 in TBS/10% donkey or sheep serum followed by 1 hr with
horseradish peroxidase-conjugated streptavidin (GE Healthcare) diluted 1:200 in TBS/10%
donkey or sheep serum. For development/visualization 3,3´-diaminobenzidine (Sigma) was
used.
Neurosphere cultures were fixed (24 hrs) in 4% neutral buffered formalin (Bie&Berntsen),
washed in a NaCl followed by treatment with plasma and thrombin (3:2 ratio). The resulting
fibrin-clot was paraffin embedded and sectioned at 3 μm. Sections were dewaxed in Xylene
CO stimulates dopaminergic differentiation
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(DAKO) and rehydrated in a graded series of ethanol. Endogenous peroxidase was inhibited
by 1.5% hydrogen peroxide/TBS (DAKO). Heat-induced epitope retrieval (DAKO) was
performed with tris-EDTA-glucose (DAKO) or target retrieval solution (DAKO) buffer
(microwave: 9 min at 900 W, 15 min at 440 W—subsequently 15 min at room temperature).
Afterwards sections were placed in an Autostainer Universal Staining System (DAKO) for 1
hr. HIF1α (1:1000; B&D Systems) in target retrieval solution buffer and carbonic anhydrase IX
(CA9; 1:1000; Novus Biologicals) in cell conditioning1 buffer. Sections were incubated for 30
min with secondary antibodies; Powervision and Optiview for HIF1α and CA9, respectively.
Visualization with 3,3´-diaminobenzidine was followed by staining with Mayer’s Hematoxylin
(DAKO).
Western blotting
Western blotting was performed as described by Krabbe et al. [59]. Membranes were incu-
bated (over night/4˚C) with anti-TH (1:2000; monoclonal mouse; Chemicon) or anti-β-tubIII
antibody (1:2000; monoclonal mouse; Sigma) diluted in TBS/Tween-20, washed, incubated (1
hr) with horseradish peroxidase-conjugated anti-mouse antibody (1:2000; DAKO) diluted in
TBS/Tween-20, developed with chemiluminiscence (SuperSignal1Extended duration sub-
strate; Thermo Scientific), and visualized using a charge coupled device camera. Loading con-
trol: alpha-actin antibody (1:6000; mouse; Chemicon).
Quantitative-Polymerase chain reaction
Messenger RNA was extracted using the High Pure RNA isolation kit (Roche Diagnostics),
and cDNA synthesis was performed using the Transcriptor High Fidelity cDNA synthesis kit
(Roche Diagnostics). PCR was performed using specific forward and reverse primers designed
for: TH (50-CGGGCTTCTCGGACCAGGTGTA-30 and 50-CTCCTCGGCGGTGTACTCCACA-
30), Nurr1 (50-CTGCAAAAGGAGACAATATAGACCA-30 and 50-ATCGTAGACCCCAGTCACA
TAA-30), Dopamine transporter (DAT; 50-TTCCTCAACTCCCAGTGTGC-30 and 50-AGGAT
GAGCTCCACCTCCTT-30), Dopamine beta-hydroxylase (DBH; 50-CTTCCTGGTCATCCTGG
TGG-30 and 50-TCCAGGGGGATGTGATAGGG-30) and ribosomal protein L22 (5’-CACGAA
GGAGGAGTGACTGG-3’and 5’-TGTGGCACACCACTGACATT-3’). Fast Start DNA Master
Plus SYBR Green I (Roche Diagnostics) was applied using the following protocol: denaturation
program, 95˚C for 10 min followed by 45 cycles of 95˚C for 10 sec, 60˚C for 10 sec and 72˚C
for 10 sec.
MTS cell viability assay
Metabolically active, viable cells undergoing proliferation were investigated using the MTS kit
(CellTiter 961AqueousOne Solution; Promega) according to the manufacturer’s instructions
and a Vmax kinetic microplate reader with SoftMax1Pro software (Molecular Devices).
High-performance liquid chromatography
Dopamine and homovanillic acid were assessed in culture medium/extracts derived from cells
differentiated (14 days) according to our standard protocol supplemented by 25 ppm CO (30
min) at days 0 and 4.
Sample preparation; medium: Cells were washed twice in Hank’s balanced salt solution (Life
Technologies), followed by incubation (2 hrs/36˚C) in 200 μl of Hank’s balanced salt solution
containing 10μM nomifensine (Research Biochemicals International). A 100 μl sample was
transferred to HPLC vials containing 50 μl of mobile phase (10% methanol (v/v), 20 g/l citric
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acid monohydrate, 100 mg/l octane-1-sulfonic acid sodium salt, 40 mg/l EDTA dissolved in
Milli-Q water and pH adjusted to 4.0; all from Merck/VWR Chemicals) and stored at -20˚C
until HPLC analysis with electrochemical detection [60,61].
Sample preparation; extracts: After removing the culture medium, 150 μl/well of 0.1 M per-
chloric acid (Merck) with antioxidants (0.2 g/L Na2S2O5, 0.05g/L Na2-EDTA; Merck) was
added. Cells were resuspended in perchloric acid, transferred to dark eppendorf vials on ice,
briefly sonicated and centrifugated (20.000 x g/20 min/4˚C). The supernatant was stored at
-20˚C until analysis.
Multi cytokine array
Conditioned culture medium was frozen (-20˚C), and cells were collected as described for
Western blotting but with the cell pellets dissolved in RayBio1 Cell Lysis Buffer (RayBioech).
Protein concentrations were determined using a protein assay (BioRad). Four membranes
(Human Cytokine Antibody Array-5; RayBiotech) were incubated (30 min/room temperature)
with blocking buffer (RayBiotech), and 1 ml conditioned culture medium or 160 μg cell lysate
(diluted to 1 ml in blocking buffer) was added (incubation; 1 hr/RT followed by 12 hrs/4˚C).
After washing, membranes were incubated with biotin-conjugated antibody diluted in block-
ing buffer (2 hrs/room temperature and 12 hrs/4˚C). Membranes were then incubated with
horseradish peroxidase-conjugated streptavidin diluted in blocking buffer (2 hrs/room tem-
perature), washed, developed with chemiluminiscence (RayBiotech), and visualized using a
charged coupled device camera (Carestream). Densitometric analysis was performed using
Image J software (NIH). Changes >50% relative to control were taken into consideration.
Measurement of reactive oxygen species (ROS)
Determination of ROS in cultured cells was performed by analysis of hydrogen peroxide
(H2O2) formation. H2O2 production was measured with a homogenous bioluminescence
ROS-Glo™H2O2 Assay Kit according to the manufacturer’s protocol (Promega). Briefly, cells
were seeded in 96-well plates (5.000 cells/ well). ROS levels were determined at day 0 (two hrs
after after the first CO exposure) and at day 6 in vitro (two days after the second CO exposure).
The ROS-Glo™H2O2 Substrate was added during treatment (final concentration 25 μM), and
the cells were incubated for an additional hours (37˚C, CO2 incubator). After incubation, 50 μl
medium from each well was transferred to 96-well plates. ROS-Glo™H2O2 Detection Solution
was added (incubation for 20 min) before luminescence was determined using an Orion L
Microplate Luminometer (Titertek Berthold). Luminescence signals were normalized to pro-
tein concentrations determined by the BCA Protein Assay Kit (Thermo Fisher Scientific).
Cell counting
Quantification of cells was performed using bright field microscopy (Olympus). Cells with an
extensive immunostaining and a well-preserved cellular structure were counted in 16 ran-
domly selected areas/well (X200) using an ocular grid (0.5x0.5 mm2).
Statistical analysis
Statistical analysis was performed using Prism GraphPad Software. Sample size estimates
were made by power analysis. Cell numbers were compared by one-way analysis of variance
(ANOVA) followed by Dunnett’s multiple comparisons test. Student’s t-test or the non-
parametric Mann-Whitney U-test was used (depending on data distribution) when comparing
only two groups. p<0.05 (), p<0.01 () and p<0.001 ().
CO stimulates dopaminergic differentiation
PLOS ONE | https://doi.org/10.1371/journal.pone.0191207 January 16, 2018 7 / 24
Results
Carbon monoxide release
To characterize and validate the reaction from the new CO-releasing molecule (CORM)
MePh2SiCO2H (Fig 1a), the CO concentration was measured in the gas chamber every
minute throughout a 30 min exposure period (Fig 1b). The CO level increased rapidly
after mixing MePh2SiCO2H, potassium fluoride and dimethyl sulfoxide, reaching the desired
concentrations after 5 min and maintaining a constant level during the entire exposure
period (S1 Fig). Calculations of CO concentrations, using available data on the CO (g) solu-
bility in water at 36˚C and 1 atmosphere, revealed relatively low levels of CO in the culture
medium, e.g. 25 ppm CO in the gas chamber would result in approximately 20 nM CO in the
medium.
Effect of CO on stem cell differentiation
To investigate the effect of CO on the dopaminergic differentiation, hVMbclXL cells were dif-
ferentiated for 6 days and received CO (12.5–100 ppm; 30 min) at days 0 and 4 (Fig 1c). The
density of TH-ir neurons increased significantly, when the cells were exposed to CO at 25 and
100 ppm compared to control (control = 8.3±0.9; 12.5 ppm CO = 9.5±1.2; 25 ppm CO = 13.8
±1.1 (p<0.001); 50 ppm CO = 10.6±1.0; 100 ppm CO = 12.1±1.1 (p<0.05); TH-ir cells/mm2;
mean±SEM; n = 29–40; four independent experiments) (Fig 2a). Moreover, the percentage of
TH-ir neurons relative to HN-ir cells (total cells) was significantly higher for cultures exposed
to CO at 25 and 100 ppm compared to control (control = 1.9±0.2; 12.5 ppm CO = 2.1±0.2;
25 ppm CO = 3.6±0.2 (p<0.001); 50 ppm CO = 2.6±0.2; 100 ppm CO = 2.8±0.2 (p<0.05); %
TH-ir cells of total cells; mean±SEM; n = 29–40; four independent experiments) (Fig 2e). Rep-
resentative digital images visualizing the content and morphology of TH-ir neurons are shown
in Fig 2h.
The density of β-tubIII-ir neurons increased significantly in cultures treated with 25–
100 ppm CO compared to control (control = 44.2±2.8; 25 ppm CO = 58.3±3.1 (p<0.01);
50 ppm CO = 58.5±2.3 (p<0.01); 100 ppm CO = 66.5±3.4 (p<0.001); β-tubIII-ir cells/mm2;
mean±SEM; n = 29–40; four independent experiments) (Fig 2b). Furthermore, the percentage
of β-tubIII-expressing neurons of total cells was significantly higher (control = 10.7±0.8;
25 ppm CO = 15.2±0.6 (p<0.001); 50 ppm CO = 15.6±0.8 (p<0.001); 100 ppm CO = 16.4±0.6
(p<0.01); % β-tubIII-ir cells of total cells; mean±SEM; n = 29–40; four independent experi-
ments) (Fig 2f). No differences in total cells were detected (Fig 2c). Representative images of β-
tubIII-ir and HN-ir cells are shown in Fig 2h.
TH and β-tubIII expression was also investigated by Western blotting showing increased
TH expression at 25 and 100 ppm CO compared to control. Moreover, there was indication of
increased β-tubIII expression in all CO treated groups (Fig 2g).
To investigate whether similar effects could be obtained for other cell lines, hREN VM cells
were treated with 25 ppm CO at days 0 and 4. A significantly higher density of β-tubIII-ir neu-
rons was detected for CO treated cultures compared to control (control = 2.9±0.3; CO = 5.7
±0.4 (p<0.001); β-tubIII-ir cells/mm2; mean±SEM; n = 10) (S3a Fig). Total cell numbers did
not differ between the groups (control = 418±9.7; CO = 439±20; HN-ir cells/mm2; mean
±SEM; n = 4). Moreover, the percentage of β-tub III-ir neurons relative to total cells was signif-
icantly higher for the CO group compared to control (control = 0.7±0.07; CO = 1.3±0.08
(p<0.001); % β-tubIII-ir cells of total cells; n = 10) (S3b Fig). Representative digital images of
β-tubIII-ir neurons and HN-ir cells are shown in S3c and S3d Fig. Western blotting analysis
for β-tubIII did not reveal differences in signal intensities between CO treated cultures and
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Fig 2. Dose response effects of short-term carbon monoxide (CO) treatment on neuronal differentiation of
human neural stem cells (hVMbclXL). Quantitative analysis of total cells (human nuclei-immunoreactive (HN-ir)
cells), cells differentiated into tyrosine hydroxylase-ir (TH-ir) and β-tubulinIII-ir (β-tubIII) neurons in 6-day-old
cultures. Cultures received CO treatment (12.5–100 ppm) for 30 min at days 0 and 4. Untreated cells served as
controls. (a) Quantification of TH-ir neurons showed a significant increase for 25 and 100 ppm CO compared to
CO stimulates dopaminergic differentiation
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controls. The number of TH-ir neurons was too low in the hREN VM cell cultures for a valid
comparison of the groups.
In summary, short-term CO exposure during stem cell differentiation has the capacity to
increase both density and relative content of TH-ir and β-tubIII-ir cells.
Effect of short versus longer-term CO exposure and role of differentiation
time
To investigate the potential role of short-term versus longer-term CO exposure, hVMbclXL
cells were treated with 25 ppm CO for 30, 45 or 60 min at day 0 and 4 and differentiated for 6
days (n-16/group; two independent experiments). All treatments resulted in significantly
higher relative contents of TH-ir cells, but no differences between the CO exposure groups
were detected (data not shown).
To address if the effect of CO was transient or long-lasting hVMbclXL cells received CO
treatment (25 ppm; 30 min) at days 0 and 4 and were differentiated for 6 or 10 days (Fig 3). At
day 6 and 10, the content of TH-ir neurons relative to β-tubIII-ir neurons had increased signif-
icantly in the CO treated groups (control 6 days = 24.7±2.1; 25 ppm CO 6 days = 32.2±2.4
(p<0.05); control 10 days = 36.7±1.7; 25 ppm CO 10 days = 45.3±1.9 (p<0.01); % TH-ir
cells of β-tubIII-ir neurons; mean±SEM; n = 17–20; two independent experiments) (Fig 3b).
Furthermore, the relative yields of TH-ir neurons of total cells had increased (control 6
days = 2.9±0.2; 25 ppm CO 6 days = 4.2±0.3 (p<0.01); control 10 days = 5.5±0.3; 25 ppm CO
10 days = 6.5±0.2 (p<0.001); % TH-ir cells of total HN-ir cells; mean±SEM; n = 17–20; two
independent experiments) (Fig 3c). At day 6 and 10, Western blotting analysis indicated
increased signal intensities for β-tub III, and at day 10 TH expression was slightly increased for
cultures exposed to CO compared to control (Fig 3a). Representative photomicrographs of
TH-ir and β-tubIII-ir neurons are shown in Fig 3d and 3e.
To investigate if a single dose of CO would be sufficient to elevate the content of TH-ir
cells, a group of cultures were exposed to 25 ppm CO at day 0 followed by differentiation for 1,
6 and 10 days. No difference was found between CO treatment and control cultures at day 1,
whereas a significant increase in TH-ir neurons was seen at 6 and 10 days after CO treatment
(data not shown). The number of HN-ir cells did not differ between CO treatment and control
cultures at any time point. Consequently, the relative content of TH-ir neurons had increased
significantly at day 6 and 10 in CO exposed cultures compared to controls.
In summary, the positive effect of CO on the relative content of TH-ir cells was not tran-
sient, and it could be obtained even with a single dose of CO.
Effect of CO on neuronal maturation and dopaminergic capacity
To investigate the potential effect of CO on neuronal maturation, numbers of mature MAP2-ir
neurons were quantified in 6-day-old cultures (25 ppm CO; 30 min; day 0 and 4 versus con-
trol). The percentage of MAP2-ir neurons of total cells was significantly higher for CO-treated
control. (b) Quantification of β-tubIII-ir neurons revealed a significant increase for cells treated with 25, 50 and
100 ppm CO. (c) No differences between numbers of HN-ir cells were seen. (d) The percentage of TH-ir neurons of β-
tubIII-ir neurons did not differ between the groups. (e) Exposure to 25 and 100 ppm CO resulted in a significant
increase in the percentage of TH-ir neurons of total cells, and (f) 25–100 ppm CO resulted in a significant increase in
the percentage of β-tubIII-ir neurons of total cells as compared to untreated controls. Data are based on four
independent experiments (n = 29-40/group) and expressed a mean±SEM (p<0.05, p<0.01, p<0.001). (g)
Western blotting for β-tubIII showed an increase in signal intensities for all CO treatment groups compared to control.
10 μg protein was loaded per lane and α-actin served as loading control. β-tubIII 50 kDa; TH 56 kDa; α-actin
43 kDa. (h) Digital images of cultures treated with CO expressing TH, β-tubIII and HN. Scale bar = 50 μm.
https://doi.org/10.1371/journal.pone.0191207.g002
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cultures (control = 5.5±0.7; CO = 7.9±0.7 (p<0.05); % MAP2-ir cells of total cells; mean±SEM;
n = 26; two independent experiments) (Fig 4a). Moreover, CO treated cells displayed a more
mature morphology with long and branching processes. Representative images of MAP2-ir
neurons can be seen in Fig 4b.
The expression of catecholaminergic/midbrain-specific genes (TH, Nurr1, DAT and DBH)
was assessed by mRNA quantification using real-time Q-PCR. TH and Nurr1 (Fig 4c) were
increased significantly after CO treatment, whereas DAT levels were lower (not shown). DBH
mRNA levels were also increased after CO treatment (not shown). HPLC analysis revealed a
significant elevation of dopamine levels in cell extracts (Fig 4d) and significantly increased
homovanillic acid levels in conditioned culture medium from cells exposed to CO compared
to controls (Fig 4e). Noradrenaline could not be detected under the chromatographic condi-
tions used.
In summary, CO treatment stimulates neuronal maturation and formation of neurons with
midbrain characteristics.
Mechanisms of action: Effects of CO on cell proliferation, apoptosis,
cytokine profile, expression of hypoxia-inducible factor-1α, and
production of ROS
To address the effect of CO on cell proliferation, hVMbclXL cells received a single dose of CO
at day 0 (25 ppm; 30 min) and were differentiated for 1, 6 or 10 days. The relative content of
proliferative cells did not differ between the groups at any time-point (control 1 day = 32.3
±3.6; CO 1 day = 34.7±3.8; control 6 days = 42.3±1.1; CO 6 days = 44.9±1.8; control 10
Fig 3. Effects of carbon monoxide (CO) on neuronal and dopaminergic differentiation. Quantitative analysis of 6- and 10-day-old cultures
(hVMbclXL) differentiated into dopaminergic neurons by exposure to 25 parts per million (ppm) CO (30 min) at days 0 and 4. Control cells followed
the same protocol but received no CO treatment. (a) Western blotting for β-tubulinIII (β-tubIII) and tyrosine hydroxylase (TH) showed a slight
increase in band intensities after CO treatment compared to controls. 15 μg protein was loaded per lane and α-actin served as a loading control. β-
tubIII 50 kDa; TH 56 kDa; α-actin 43 kDa. (b) At day 10, the percentages of TH-immunoreactive (-ir) neurons of total neurons (β-tubIII) were
significantly higher for the CO treatment groups compared to control. (c) At days 6 and 10 also the percentages of TH-ir neurons of total cells (human
nuclei (HN)-ir cells) were significantly increased for the CO treatment groups (n = 17–20; two independent experiments). Data are expressed as mean
±SEM (p<0.05, p<0.01, p<0.001). (d, e) Representative digital images of TH-ir neurons displaying a mature neuronal morphology with long
processes. Scale bar = 50 μm. Con = control.
https://doi.org/10.1371/journal.pone.0191207.g003
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days = 59.9±3.8; CO 10 days = 63.8±4.3; % Ki67-ir cells of total cells; mean±SEM; n = 12–14;
two independent experiments). However, the overall percentage of Ki67-ir cells was found to
increase during the differentiation from day 1 to 10 (Fig 5a). Representative photomicrographs
of Ki67-ir cells are shown in Fig 5b. Further evaluation of metabolically active, viable cells in
proliferation was performed by measuring MTS tetrazolium reduction in 6-day-old cultures
receiving 25 ppm CO treatment (30 min) at days 0 and 4 compared to control. The analysis
revealed no difference between the groups (Fig 5c). In summary, CO does not modulate cell
Fig 4. Characterization of neuronal cells in differentiated cultures. Assessment of neuronal maturation of
hVMbclXL cells receiving 25 parts per million (ppm) CO treatment (30 min) at days 0 and 4 and differentiated for 6,
10 and 14 days. Control cultures followed the same protocol but received no CO treatment. (a) Percentage of
microtubule-associated protein2ab-immunoreactive (MAP2-ir) neurons of total cells showed a significant increase for
cultures treated with CO compared to controls (control = 5.52±0.71; CO = 7.98±0.69 (p<0.05); % Map2-ir cells of total
cells; mean±SEM; n = 26; two independent experiments). Data are expressed as mean±SEM. (b) Digital images of
MAP2-ir neurons showing mature neuronal morphology with long processes. Scale bar = 50 μm. (c) Quantitative
mRNA analysis of hVMbclXL cells receiving 25 ppm CO treatment at days 0 and 4 and differentiated for 10 days.
Control cells followed the same protocol but received no CO treatment. Quantities of mRNA were compared with
mRNA levels at day 0. Tyrosine hydroxylase (TH) and Nurr1 mRNA levels were significantly increased for cultures
treated with CO compared to controls. (d,e) HPLC analysis for dopamine (DA) in cell extracts (n = 10–11; p<0.01)
and the DA metabolite homovanillic acid (HVA) in conditioned culture medium (n = 11–12; p<0.001) from
untreated controls and cultures receiving 25 ppm CO at days 0 and 4 and differentiated for 14 days. The analyses
revealed significant elevations in both DA and HVA for cultures treated with CO compared to controls.
https://doi.org/10.1371/journal.pone.0191207.g004
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proliferation during neuronal differentiation. To evaluate the potential effect of CO on apopto-
sis, 6-day-old cultures receiving 25 ppm CO treatment (30 min) at days 0 and 4 were immu-
nostained for active/cleaved Casp3. The relative content of Casp3-ir cells was significantly
reduced after CO treatment (control = 0.3±0.03; CO = 0.2±0.02 (p<0.001); % Casp3-ir cells of
total cells; mean±SEM; n = 26; two independent experiments) (Fig 5d).
To address whether CO had an effect on cytokine profiles (conditioned culture medium/
cell lysates), multi-cytokine analysis was performed using hVMbclXL cells receiving 25 ppm
CO (30 min) at days 0 and 4 and differentiated for 5 days versus untreated controls (Fig 6).
Densitometric analysis indicated a reduction in the release of neurotrophin-3 (0.5 fold) and an
increase in neurotrophin-4 (2.4 fold), vascular endothelial growth factor (2.3 fold), and osteo-
pontin (1.9 fold) in cells receiving CO (Fig 6). The conditioned culture medium revealed a
reduction in interleukin-15 (0.4 fold) and interferon-γ (0.5 fold) levels and an increase in insu-
lin-like growth factor binding protein-4 (IGFBP-4; 1.7 fold) after CO treatment (Fig 6).
To investigate whether CO treatment had an effect on HIF1α stabilization and the expres-
sion of a HIF1α regulated enzyme, CA9, hVMbclXL cells were grown in non-adherent culture
until neurospheres were visible. Neurospheres then received 25 ppm CO (30 min) at days 0
and 4 and were grown for 9 days (n = 16–18; two independent experiments). Immunostaining
for HIF1α revealed a significant increase in the number of HIF1α-ir cells for cultures receiving
Fig 5. Effects of carbon monoxide (CO) treatment on proliferation and apoptosis. Assessment of proliferation in
hVMbclXL cells receiving 25 parts per million (ppm) CO at day 0 (30 min) and differentiated for 1, 6 and 10 days and
apoptosis in cultures receiving 25 ppm CO treatment (30 min) at days 0 and 4 and differentiated for 6 days. Control
cells followed the same protocol but received no CO treatment. (a) The percentage of Ki67-immunoreactive (Ki67-ir)
cells of Human Nuclei (HN)-ir cells showed no difference between CO treatment and control cultures at any time-
point (n = 12–14; two independent experiments). (b) Representative digital images of Ki67-ir cells receiving 25 ppm
CO treatment at day 0 and differentiated for 1, 6 and 10 days. (c) Analyses of MTS reduction in cultures receiving
25 ppm CO treatment at days 0 and 4 and differentiated for 6 days did not differ between the groups. (d) The
percentage of active/cleaved Caspase3 (Casp3)-ir apoptotic cells of total cells was significantly reduced for cultures
receiving CO compared to controls (n = 26; two independent experiments). Data are expressed as mean±SEM
(p<0.001). (e) Digital images of Casp3-ir cells. Scale bar = 50 μm.
https://doi.org/10.1371/journal.pone.0191207.g005
CO stimulates dopaminergic differentiation
PLOS ONE | https://doi.org/10.1371/journal.pone.0191207 January 16, 2018 13 / 24
CO compared to controls (Fig 7a and 7b–7d). Accordingly, neurospheres exposed to CO dis-
played more immunoreactivity to CA9 than untreated controls (Fig 7c).
To investigate whether the observed effect of CO also involved changes in levels of reactive
oxygen species (ROS), ROS was assessed at 2 and 48 hrs after CO treatment (25 ppm, 30 min)
(Fig 7e). The analysis showed that ROS levels were significantly elevated (p<0.001) at both
Fig 6. Effects of carbon monoxide (CO) treatment on cytokine profiles. Semi-quantitative expression profile of cytokines in cells (hVMbclXL) and
conditioned medium from cultures receiving 25 parts per million (ppm) CO treatment (30 min) at days 0 and 4 and differentiated for 5 days compared
to untreated controls. (a) Digital images of signal intensities for representative arrays containing 80 different cytokines plus positive and negative
staining controls. Selected key changes in the arrays, representing the compiled dataset, are highlighted by red (up-regulation) and green circles (down-
regulation). (b) Schematic overview illustrating the different cytokines. Densitometric analysis and comparison of signal intensities indicated an
increase for vascular endothelial growth factor (VEGF), neurotrophin-4 (NT-4) and ostepontin and a relative reduction for neurotrophin-3 (NT-3) in
cells receiving CO compared to controls. The content of cytokines in the medium indicated an increase for insulin-like growth factor binding protein 4
(IGFBP-4) and a reduction in interferon-γ (IFN-γ) and interleukin-15 (IL-15) for cultures treated with CO compared to control.
https://doi.org/10.1371/journal.pone.0191207.g006
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time-points investigated (day 0, two hrs after CO exposure: control = 8593±437 relative light
units (RLU) versus CO group = 15940±402 RLU and day 6, 48 hrs after CO exposure: control
15399±380 RLU versus CO group = 21165±643 RLU; mean±SEM; n = 6; two independent
experiments).
Fig 7. Effect of carbon monoxide (CO) treatment on stabilization of hypoxia inducible factor1α (HIF1α) and levels of reactive oxygen species
(ROS). Assessment of HIF1α-immunoreactive (-ir) and carbonic anhydraseIX (CA9)-ir cells in hVMbclXL cultures propagated as neurospheres. Cells
received 25 parts per million (ppm) CO (30 min) at days 0 and 4 and were grown for 6–9 days. (a, b) Representative photomicrographs of HIF1α-ir cells
in thin sections from CO-treated and untreated neurospheres (insert: negative control; omission of primary antibody (Ab)). (c) Photomicrographs of
CA9, a protein regulated by HIF1α, in sections from neurosphere cultures receiving CO versus control (insert: negative control). (d) Densitometric
analysis of HIF1α-ir cells (values normalized to area of interest) revealed a significant increase in sections from cultures treated with CO compared to
control. Scale bars = 50 μm. (e) Assessment of ROS in differentiating hVMbclXL monolayer cultures at day 0 (2 hrs after first CO exposure) and at day 6
(48 hrs after second CO treatment). At both time-points, ROS levels were significantly elevated (p<0.001) after CO treatment (25 ppm CO (30 min);
RLU: relative light units).
https://doi.org/10.1371/journal.pone.0191207.g007
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In summary, the complex mechanisms underlying the observed effects of CO on stem cell
differentiation involve a reduction of apoptotic cell death, a changed cytokine profile, stabiliza-
tion of HIF1α and elevated ROS levels but do not influence cell proliferation.
Discussion
In the present study, CO was generated by a decarbonylation reaction using the new CORM
methyldiphenylsilacarboxylic acid (MePh2SiCO2H), along with the non-transition-metal acti-
vator potassium fluoride and dimethyl sulfoxide. This new strategy avoids the use of CO gas
bottles, thus being more simple, safer and more cost-effective than previously described meth-
ods. To our knowledge, this is also the first paper to report a positive effect of CO on dopami-
nergic differentiation of human neural stem cells (NSCs). In brief, two stem cell lines were
exposed to low levels of CO during their differentiation. Short-term CO treatment significantly
increased both the numbers and relative yields of β-tubIII-ir neurons, suggesting that CO
treatment stimulates neurogenesis. Moreover, the relative content of TH-ir neurons was signif-
icantly increased after CO exposure (Fig 3), which suggests that CO treatment favors induction
or survival of the catecholaminergic phenotype. Exposure of hVMbclXL cells to CO also
increased the number of MAP2-ir neurons (Fig 4a), indicating that CO affects neuronal matu-
ration. Control experiments using inactive CORMs (iCORMs) confirmed that the observed
effects were due to the release of CO and not the reagents used to initiate the chemical reaction
(S4 Fig).
Many biological effects of CO are associated with generation of low levels of reactive oxygen
species, which act as signaling molecules [21–23,62–64]. CO-induced reactive oxygen species
generation is mainly due to partial inhibition of cytochrome C oxidase [65–67]. Interestingly,
stimulation of reactive oxygen species production is also important for cell signaling during
neuronal differentiation and/or survival of embryonic stem cells, mesenchymal stem cells and
neuronal progenitor cells [21,24,66,67].
In our study, CO treatment did not alter the total number of cells. Furthermore, the MTS
analysis used to assess cell proliferation and viability revealed no change after CO treatment,
which was in line with the unchanged content of HN-ir cells (Fig 5). Thus, it is unlikely that
the applied CO concentrations influenced cell proliferation or were toxic to the cells. This is to
some extent in accordance with studies showing an anti-proliferative effect of CO in other tis-
sues, including vascular smooth muscle cells and T-lymphocytes, through activation of mito-
gen-activated protein kinases and the cell cycle inhibitor p21 [16,68,69].
Interestingly, studies exposing NSCs to low oxygen tension have reported both increased
cell proliferation and dopaminergic differentiation [14,70]. In the present study using CO
exposure in ambient oxygen, dopaminergic differentiation was increased without an increase
in cell proliferation, which suggests other underlying mechanisms than those triggered by low
oxygen.
Previous studies have shown an anti-apoptotic effect of CO treatment on fibroblasts, endo-
thelial cells, astrocytes and cerebellar granule cells [21,23,71,72]. To address whether a similar
effect was present in hVMbclXL cells, cultures were immunostained for active/cleaved Casp3.
The relative content of Casp3-ir cells was significantly reduced after CO, indicating that CO
has an anti-apoptotic effect. However, the number of Casp3-ir cells was very low most likely
due to the over-expression of the anti-apoptotic protein BclXL, which should be taken into
account. Interestingly, Almeida and colleagues have recently demonstrated that CO increases
neuronal differentiation in hippocampal slice cultures, NT2 and SH-Y5Y cells by limiting apo-
ptosis [35]. The specific molecular mechanism by which CO suppresses apoptosis was beyond
the scope of the present study, but it is likely to involve p38 MAP kinases.
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For characterization of the catecholaminergic cell population obtained after CO treatment,
the expression of catecholaminergic/midbrain-specific genes (TH, Nurr1, DAT and DBH) was
assessed by real-time Q-PCR (Fig 4c). Nurr1 is involved in maintenance of midbrain dopami-
nergic activity and is related to dopaminergic differentiation since Nurr1-null mouse-derived
NSCs fail to differentiate and express TH [73,74]. In the present study, Nurr1 expression was
increased after CO exposure, which is in line with the observed increase in TH expression and
release of dopamine and homovanilic acid. This could indicate that a substantial fraction of
neurons was dopaminergic.
The levels of dopamine in neuronal cells can be modulated by the activity of DAT and
DBH. DAT is responsible for dopamine transport from the synaptic cleft, and surprisingly it
was down-regulated after CO treatment. This may be due to the significant increase in the
pool of free dopamine after CO treatment and/or due to the artificial in vitro conditions. The
observed increase in DBH after CO treatment, which catalyses the conversion of dopamine
into noradrenaline, may simply reflect the rise of intracellular dopamine levels as a result of
TH up-regulation.
Semi-quantitative cytokine profiling of cell lysates and conditioned culture medium
showed an increase in vascular endothelial growth factor for CO-treated cultures (cell
lysates) compared to controls (Fig 6). This is consistent with other studies demonstrating
that CO elevates vascular endothelial growth factor levels in astrocytes and cardiomyocytes
[75–77]. Interestingly, a reduction in neurotrophin-3 and an increase in neurotrophin-4
levels were found in cell lysates from cultures receiving CO treatment. No studies have
investigated the effect of CO treatment on neurotrophin-3 and neurotrophin-4, but both
neurotrophins have been reported to be involved in neuronal growth, synapse formation,
maturation and plasticity. Moreover neurotrophin-3 is expressed in NSCs, stimulating their
neuronal differentiation and survival [78–80]. The down-regulation of neurotrophin-3 may
reflect the observed stimulatory effect of CO on neurogenesis and cell maturation leading to
a reduction in the pool of NSCs. On the other hand the observed up-regulation of neurotro-
phin-4 could potentially stimulate further maturation and growth of cells, which, at day 5,
are still undergoing differentiation. An increase in osteopontin expression was also found in
CO-treated cultures, which to some extent is consistent with another study, showing that
heme oxygenase-1 activity increased osteopontin expression and promoted differentiation of
odontoblasts [81].
The cytokine profiling of conditioned culture medium revealed changes for interleukin-
15, interferon-γ and IGFBP-4 after CO treatment (Fig 6). The decrease in interleukin-15
observed for CO-treated cultures could indicate that CO exhibit an anti-inflammatory effect
on NSCs. Previous studies have demonstrated that interleukin-15 is a pro-inflammatory cyto-
kine present in both NSCs and differentiated neurons during inflammation, but it has also
been reported that decreased levels of interleukin-15 in vivo leads to an increase in cell differ-
entiation and reduction in cell proliferation [82–84]. Interestingly, a study culturing rat NSCs
showed that interleukin-15 treatment reduced the number of MAP2-ir neurons thus inhibiting
neuronal maturation [85]. The observed decrease of interleukin-15 found in our study may
therefore have contributed to increased cell maturation as shown by the increased number of
MAP2-ir neurons found after treatment. The reduction in interferon-γ in cultures receiving
CO also suggests an anti-inflammatory role of CO since existing literature describe pro-
inflammatory characteristics of interferon-γ [32].
Previous studies have shown that IGFBP-4 plays a role in the developing brain by stimulat-
ing neuronal differentiation of NSCs. In the present study the increase in IGFBP-4 in cultures
receiving CO could indicate that CO signals through IGFBP-4 to promote cell differentiation
[86,87].
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Culturing of human NSCs at low oxygen tension has been shown to favor their dopaminer-
gic differentiation [59,70,88,89]. During fetal development and even in the adult brain the
physiological oxygen tension is relatively low (1–5%) [90]. Low oxygen tension stabilizes the
transcription factor HIF1α, which leads to up-regulation vascular endothelial growth factor
and erythropoietin [88,91–94]. Previous studies have suggested that also CO can stabilize
HIF1α [52,75,95]. In the present study, immunostaining for HIF1α revealed an increase in
HIF1α expression in cultures receiving CO compared to controls. This, together with the
detected increase in vascular endothelial growth factor, could indicate that the observed effect
CO on NSCs to some extent mimics effects of low oxygen, by stabilizing HIF1α [94,96,97] (Fig
7). However, our additional finding of a significant and long-lasting elevation in ROS levels
after treatment clearly indicates that CO has a more complex mechanism of action.
Conclusion
Short-term treatment of differentiating human neural stem cells with a low dose of CO, pro-
duced by CO-releasing compounds, represents an efficient, simple, cost-effective and safe
method for in vitro derivation of viable dopaminergic neurons with midbrain characteristics.
This finding may have implications for the derivation of cells for experimental studies and
future development of donor cells for potential transplantation in Parkinson’s disease.
Supporting information
S1 Fig. Repeated measure of carbon monoxide (CO) levels in the CO chamber during the
30 min exposure period. Measurements visualized in the figure represent data from the analy-
sis of 4 different CO concentrations (12.5–100 parts per million (ppm)). Data are expressed as
mean±SEM (12.5 ppm: n = 4; 25 ppm: n = 5; 50 ppm: n = 5; 100 ppm: n = 5 at each time point;
4–5 independent experiments).
(TIF)
S2 Fig. Analysis of cells by a NucleoCounter1 NC-200. Neural stem cells (hVMbclXL) were
dissociated using trypsin/EDTA, centrifuged for 5 min at 800 rpm and 4˚C, resuspended in
culture medium and loaded on the automatic cell analyzer. (a) Data on cell viability, cell diam-
eter and density. (b) Image of cells counted in the sample. (c) Graph representing cells stained
with Acridine Orange (AO), marking all viable and non-viable cells and their distribution in a
Via1-Cassette, revealed that 90% of the cells were located in the squared area of counting. (d,e)
The intensity and location of cells stained with AO. (f) Non-viable cells stained with 4’,6-dia-
midino-2-phenylindole and their distribution in the Via1-Cassette. (g,h) The intensity and
location of cells stained with 4’,6-diamidino-2-phenylindole.
(TIF)
S3 Fig. Effects of carbon monoxide (CO) treatment on neuronal differentiation of neural
stem cells. Human REN VM cells were plated in laminin-coated trays at a density of 26,000
cells/cm2 and differentiated for 6 days. One group of cultures was treated with 25 parts per mil-
lion (ppm) CO for 30 min at days 0 and 4. Control cells received no CO treatment. (a) Quanti-
fication of β-tubulinIII-immunoreactive (β-tubIII-ir) neurons showed a significant increase
for CO-treated cultures compared to control. (b) The percentage of β-tubIII-ir neurons of
human nuclei (HN)-ir cells (total cells) was significantly higher for the CO treatment group
compared to control (n = 10). Data are expressed as mean±SEM (p<0.001). (c,d) Represen-
tative digital photomicrographs of β-tubIII-ir neurons and HN-ir cells in CO-treated and con-
trol cultures. Scale bar = 50μm.
(TIF)
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S4 Fig. Test of inactive carbon monoxide releasing molecules (iCORMs) on dopaminergic
differentiation. To validate that the observed effect of the CORMs on dopaminergic differen-
tiation was mediated by CO, hVMbcl-xl cells were exposed to iCORMs (potassium flouride,
1,25 mg; dimethyl sulfoxide, 0.25 ml) for 30 min at days 0 and 4 and differentiated for 6 days.
Cultures kept under the same conditions but without exposure to CORMs served as a refer-
ence and additional control. At day 6, cultures were immunostained for tyrosine hydroxylase
(TH) and human nuclei (HN; total cells). (a) The relative content of TH-immunoreactive
(-ir) neurons, revealed no significant difference between the iCORM exposure group and the
untreated control group (n = 11–20). Data are expressed as mean±SEM.
(TIF)
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